NULISA™ Platform
The NULISA™ Platform sets a new standard in proteomic analysis with attomolar sensitivity, allowing for unprecedented biomarker detection and quantitation.
By leveraging a proprietary sequential immunocomplex capture and release mechanism and the latest advances in Next-Generation Sequencing (NGS), the NULISA technology provides both ultra-high sensitivity and scalable multiplexing.
ULTRA HIGH SENSITIVTY
Raising the Bar by
Lowering the Limit (of Detection)
Ultra-high attomolar sensitivity and lower limits of detection for the discovery and detection of critical biomarkers.
BROAD DYNAMIC RANGE
Measuring Changes Across the Biological Spectrum
With single plex up to 7 logs and multiplex up to 12 logs of dynamic range, NULISA enables quantitation across a broad range of biological expression levels without the need for dilution.
FLEXIBLE PLEX
Scaling from Single-plex to Multiplex
Flexible, scalable chemistry provides the ability to focus in on a single target, or multiplex hundreds to potentially thousands of targets in a single sample on one platform.
NULISA assays maintain performance from single qPCR to multiplex NGS analyses.
Fully Automated Workflow
Single-plex results in <8 hours and multiplex results in <15 hours with <30 minutes total hands-on time with the ARGO™ HT System
Single-plex Workflow
Multiplex Workflow
The Future of Proteomics
Proteomics promises to revolutionize how institutional, biotech, and biopharma researchers approach medicine. To maximize the utility of liquid biopsy protein biomarkers, scientists need proteomics platforms that achieve the following:
- High sensitivity and selectivity
- Broad dynamic range
- High degrees of target and sample multiplexing
- Seamless automation compatibility
The NULISA™ platform is the future of protein biomarker discovery and analysis. This next-generation proteomics technology is the first to deliver on all four liquid biopsy protein profiling needs with best-in-class capabilities:
- Attomolar (low fg/ml) sensitivity and low cross-reactivity
- ~10-log dynamic range covering low- and high-abundance targets
- Curated panels of hundreds of disease-relevant markers with NGS-capable sample-mixing in one well
- Purpose-built, sample-to-sequence automated system with excellent intra- and inter-plate precision
Whether your research goals comprise deciphering the molecular underpinnings of disease, screening potential drug candidates, or identifying translatable biomarkers that stratify patients in clinical trials, NULISA delivers actionable insights with precision, accuracy, and efficiency.
Accurately measuring protein markers in biofluids poses an enormous challenge due to the impressively wide dynamic range of proteomic concentrations, particularly for the least abundant proteins that are invaluable in early disease detection. NULISA addresses these limitations by reducing the background assay noise with a proprietary second capture step and including prediluted high abundance markers in panels. The result is the tool you’ve been waiting for to undertake complex biomarker studies and support delivering better therapies faster for patients.
Automated, hands-free workflows reduce inter-operator and inter-site variability while liberating valuable scientist and technician time from the bench to tackle more challenging initiatives. Alamar has turned NULISA technology into a turnkey protein analysis workstation with the ARGO™ HT System. Offering ease of integration into existing workflows, its purpose-built design will become a cornerstone of your biomarker research, providing rapid, reliable results with minimal intervention.
Alamar Biosciences is pushing the boundaries of what’s possible in biomarker research with NULISA. Together, we can unlock the power of the proteome—one or many biomarkers at a time.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
